The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease
PLOS Biology · 2025
DOI: 10.1371/journal.pbio.3002974 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Lijun Dai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Cholesterol 24-Hydroxylase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of Chin, National Natural Science Foundation of China, Innovative Research Groups of Hubei Province.
Abstract (Originalsprache)
Parkinson’s disease (PD) is a neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies that are composed of aggregated α-synuclein (α-Syn). However, the factors that regulate α-Syn pathology and nigrostriatal dopaminergic degeneration remain poorly understood. Previous studies demonstrate cholesterol 24-hydroxylase (CYP46A1) increases the risk for PD. Moreover, 24-hydroxycholesterol (24-OHC), a brain-specific oxysterol that is catalyzed by CYP46A1, is elevated in the cerebrospinal fluid of PD patients. Herein, we show that the levels of CYP46A1 and 24-OHC are elevated in PD patients and increase with age in a mouse model. Overexpression of CYP46A1 intensifies α-Syn pathology, whereas genetic removal of CYP46A1 attenuates α-Syn neurotoxicity and nigrostriatal dopaminergic degeneration in the brain. Moreover, supplementation with exogenous 24-OHC exacerbates the mitochondrial dysfunction induced by α-Syn fibrils. Intracerebral injection of 24-OHC enhances the spread of α-Syn pathology and dopaminergic neurodegeneration via elevated X-box binding protein 1 (XBP1) and lymphocyte-activation gene 3 (LAG3) levels. Thus, elevated CYP46A1 and 24-OHC promote neurotoxicity and the spread of α-Syn via the XBP1–LAG3 axis. Strategies aimed at inhibiting the CYP46A1-24-OHC axis and LAG3 could hold promise as disease-modifying therapies for PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.
- PET-CT/MRI Center, Molecular Imaging Center, Renmin Hospital of Wuhan University, Wuhan, China.
- TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
ORCID-Profile: Lijun Dai, Zhentao Zhang
Förderung
- National Key Research and Development Program of Chin
- National Natural Science Foundation of China
- Innovative Research Groups of Hubei Province
- Medical Science Advancement Program of Wuhan University
- “New 20 Terms of Universities in Jinan” grant
Zitieren
APA
Dai, L., Wang, J., Meng, L., Zhang, X., Xiao, T., Deng, M., Chen, G., Xiong, J., Ke, W., Hong, Z., Bu, L., & Zhang, Z. (2025). The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002974
Vancouver
Dai L, Wang J, Meng L, Zhang X, Xiao T, Deng M, et al. The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease. PLOS Biology. 2025. doi:10.1371/journal.pbio.3002974
BibTeX
@article{Dai2025,
author = {Dai, Lijun and Wang, Jiannan and Meng, Lanxia and Zhang, Xingyu and Xiao, Tingting and Deng, Min and Chen, Guiqin and Xiong, Jing and Ke, Wei and Hong, Zhengyuan and Bu, Lihong and Zhang, Zhentao},
title = {The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease},
journal = {PLOS Biology},
year = {2025},
doi = {10.1371/journal.pbio.3002974}
}
EUVIMED